Trial Profile
A Multicenter, Randomized, Double Blind, Phase III Study of BAT1706 Versus EU Avastin Plus Chemotherapy in Patients With Advanced Non Squamous Non Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Biothera
- 07 Dec 2023 According to a Bio-Thera Solutions media release, United States Food and Drug Administration has approved Avzivi (bevacizumab-tnjn), a biosimilar referencing Avastin.
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 28 Jan 2021 According to a Bio-Thera Solutions media release, based on the data from this study and a few other studies, U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for BAT1706, a proposed biosimilar to Avastin (bevacizumab).The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is November 27, 2021.